Selected research
Industry Research
Cancer Immunotherapy Drug Industry Research Report 2026
Market perspective
The global Cancer Immunotherapy Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Immunotherapy Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cancer Immunotherapy Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Immunotherapy Drug include Novartis AG, Merck & Co., Inc., Jiangsu Hengrui Medicine Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Roche Holding AG, Medimmune, LLC and Juno Pharmaceuticals Pty Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Immunotherapy Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Immunotherapy Drug Market by Company
Novartis AG
Merck & Co., Inc.
Jiangsu Hengrui Medicine Corporation
Pfizer, Inc.
Bristol-Myers Squibb Company
AstraZeneca plc
Roche Holding AG
Medimmune, LLC
Juno Pharmaceuticals Pty Ltd.
Incyte Corporation
Gilead Sciences, Inc. (Kite Pharma)
Celgene Corporation
bluebird bio, Inc.
BeiGene
Autolus Therapeutics plc
Cancer Immunotherapy Drug Segment by Type
T-Cell Stimulant
PDL-1 Inhibitor
PD-1 Inhibitor
CTLA Antibody
Cancer Immunotherapy Drug Segment by Application
Hospital
Clinic
Others
Cancer Immunotherapy Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Immunotherapy Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Immunotherapy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- T-Cell Stimulant
- PDL-1 Inhibitor
- PD-1 Inhibitor
- CTLA Antibody
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- Jiangsu Hengrui Medicine Corporation
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Roche Holding AG
- Medimmune, LLC
- Juno Pharmaceuticals Pty Ltd.
- Incyte Corporation
- Gilead Sciences, Inc. (Kite Pharma)
- Celgene Corporation
- bluebird bio, Inc.
- BeiGene
- Autolus Therapeutics plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cancer Immunotherapy Drug Market Size (2021-2032)
- 2.2.2 Global Cancer Immunotherapy Drug Sales (2021-2032)
- 2.2.3 Global Cancer Immunotherapy Drug Market Average Price (2021-2032)
- 2.3 Cancer Immunotherapy Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 T-Cell Stimulant
- 2.3.3 PDL-1 Inhibitor
- 2.3.4 PD-1 Inhibitor
- 2.3.5 CTLA Antibody
- 2.4 Cancer Immunotherapy Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cancer Immunotherapy Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cancer Immunotherapy Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Cancer Immunotherapy Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Cancer Immunotherapy Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Cancer Immunotherapy Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cancer Immunotherapy Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cancer Immunotherapy Drug, Product Type & Application
- 3.8 Global Manufacturers of Cancer Immunotherapy Drug, Established Date
- 3.9 Global Cancer Immunotherapy Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Jiangsu Hengrui Medicine Corporation
- 4.3.1 Jiangsu Hengrui Medicine Corporation Company Information
- 4.3.2 Jiangsu Hengrui Medicine Corporation Business Overview
- 4.3.3 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio
- 4.3.5 Jiangsu Hengrui Medicine Corporation Recent Developments
- 4.4 Pfizer, Inc.
- 4.4.1 Pfizer, Inc. Company Information
- 4.4.2 Pfizer, Inc. Business Overview
- 4.4.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
- 4.4.5 Pfizer, Inc. Recent Developments
- 4.5 Bristol-Myers Squibb Company
- 4.5.1 Bristol-Myers Squibb Company Company Information
- 4.5.2 Bristol-Myers Squibb Company Business Overview
- 4.5.3 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio
- 4.5.5 Bristol-Myers Squibb Company Recent Developments
- 4.6 AstraZeneca plc
- 4.6.1 AstraZeneca plc Company Information
- 4.6.2 AstraZeneca plc Business Overview
- 4.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
- 4.6.5 AstraZeneca plc Recent Developments
- 4.7 Roche Holding AG
- 4.7.1 Roche Holding AG Company Information
- 4.7.2 Roche Holding AG Business Overview
- 4.7.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
- 4.7.5 Roche Holding AG Recent Developments
- 4.8 Medimmune, LLC
- 4.8.1 Medimmune, LLC Company Information
- 4.8.2 Medimmune, LLC Business Overview
- 4.8.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
- 4.8.5 Medimmune, LLC Recent Developments
- 4.9 Juno Pharmaceuticals Pty Ltd.
- 4.9.1 Juno Pharmaceuticals Pty Ltd. Company Information
- 4.9.2 Juno Pharmaceuticals Pty Ltd. Business Overview
- 4.9.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
- 4.9.5 Juno Pharmaceuticals Pty Ltd. Recent Developments
- 4.10 Incyte Corporation
- 4.10.1 Incyte Corporation Company Information
- 4.10.2 Incyte Corporation Business Overview
- 4.10.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
- 4.10.5 Incyte Corporation Recent Developments
- 4.11 Gilead Sciences, Inc. (Kite Pharma)
- 4.11.1 Gilead Sciences, Inc. (Kite Pharma) Company Information
- 4.11.2 Gilead Sciences, Inc. (Kite Pharma) Business Overview
- 4.11.3 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio
- 4.11.5 Gilead Sciences, Inc. (Kite Pharma) Recent Developments
- 4.12 Celgene Corporation
- 4.12.1 Celgene Corporation Company Information
- 4.12.2 Celgene Corporation Business Overview
- 4.12.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
- 4.12.5 Celgene Corporation Recent Developments
- 4.13 bluebird bio, Inc.
- 4.13.1 bluebird bio, Inc. Company Information
- 4.13.2 bluebird bio, Inc. Business Overview
- 4.13.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
- 4.13.5 bluebird bio, Inc. Recent Developments
- 4.14 BeiGene
- 4.14.1 BeiGene Company Information
- 4.14.2 BeiGene Business Overview
- 4.14.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
- 4.14.5 BeiGene Recent Developments
- 4.15 Autolus Therapeutics plc
- 4.15.1 Autolus Therapeutics plc Company Information
- 4.15.2 Autolus Therapeutics plc Business Overview
- 4.15.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
- 4.15.5 Autolus Therapeutics plc Recent Developments
5 Global Cancer Immunotherapy Drug Market Scenario by Region
- 5.1 Global Cancer Immunotherapy Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cancer Immunotherapy Drug Sales by Region: 2021-2032
- 5.2.1 Global Cancer Immunotherapy Drug Sales by Region: 2021-2026
- 5.2.2 Global Cancer Immunotherapy Drug Sales by Region: 2027-2032
- 5.3 Global Cancer Immunotherapy Drug Revenue by Region: 2021-2032
- 5.3.1 Global Cancer Immunotherapy Drug Revenue by Region: 2021-2026
- 5.3.2 Global Cancer Immunotherapy Drug Revenue by Region: 2027-2032
- 5.4 North America Cancer Immunotherapy Drug Market Facts & Figures by Country
- 5.4.1 North America Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cancer Immunotherapy Drug Sales by Country (2021-2032)
- 5.4.3 North America Cancer Immunotherapy Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cancer Immunotherapy Drug Market Facts & Figures by Country
- 5.5.1 Europe Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cancer Immunotherapy Drug Sales by Country (2021-2032)
- 5.5.3 Europe Cancer Immunotherapy Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cancer Immunotherapy Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cancer Immunotherapy Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cancer Immunotherapy Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cancer Immunotherapy Drug Market Facts & Figures by Country
- 5.7.1 South America Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cancer Immunotherapy Drug Sales by Country (2021-2032)
- 5.7.3 South America Cancer Immunotherapy Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cancer Immunotherapy Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cancer Immunotherapy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cancer Immunotherapy Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cancer Immunotherapy Drug Sales by Type (2021-2032)
- 6.1.1 Global Cancer Immunotherapy Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Cancer Immunotherapy Drug Revenue by Type (2021-2032)
- 6.2.1 Global Cancer Immunotherapy Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Cancer Immunotherapy Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cancer Immunotherapy Drug Sales by Application (2021-2032)
- 7.1.1 Global Cancer Immunotherapy Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Cancer Immunotherapy Drug Revenue by Application (2021-2032)
- 7.2.1 Global Cancer Immunotherapy Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Cancer Immunotherapy Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cancer Immunotherapy Drug Value Chain Analysis
- 8.1.1 Cancer Immunotherapy Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cancer Immunotherapy Drug Production Mode & Process
- 8.2 Cancer Immunotherapy Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cancer Immunotherapy Drug Distributors
- 8.2.3 Cancer Immunotherapy Drug Customers
9 Global Cancer Immunotherapy Drug Analyzing Market Dynamics
- 9.1 Cancer Immunotherapy Drug Industry Trends
- 9.2 Cancer Immunotherapy Drug Industry Drivers
- 9.3 Cancer Immunotherapy Drug Industry Opportunities and Challenges
- 9.4 Cancer Immunotherapy Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst